Definition And Pathophysiology
- The Krebs cycle (Tricarboxylic Acid cycle) is the central metabolic pathway in the mitochondrial matrix responsible for the final oxidation of carbohydrates, lipids, and amino acids.
- Physiologic Functions: Generates high-energy electron carriers (NADH, FADH2) for oxidative phosphorylation and provides intermediates for the synthesis of amino acids, heme, and neurotransmitters.
- Pathophysiology Of Defects: Impaired ATP production causes energy failure affecting the brain, heart, and muscle. Blockage of the cycle prevents the entry of pyruvate, shunting it toward lactate, resulting in severe lactic acidosis. Specific toxic organic acids, such as fumarate or alpha-ketoglutarate, accumulate proximal to the enzymatic blocks.
Classification And Specific Disorders
| Disorder | Genetics And Mechanism | Biochemical Profile | Clinical Phenotype |
|---|---|---|---|
| Alpha-Ketoglutarate Dehydrogenase Deficiency | Mutations in the DLD gene affecting the E3 subunit (shared with PDH and BCKDH). | Elevated alpha-ketoglutarate, lactate, pyruvate, and branched-chain ketoacids. | Early infancy onset, progressive neurologic deterioration, hypotonia, ataxia, and Leigh syndrome. |
| Succinate Dehydrogenase (SDH) Deficiency | Mutations in SDHA. Affects both the Krebs cycle and Complex II of the Electron Transport Chain. | - | Infantile Leigh syndrome, hypertrophic or dilated cardiomyopathy, and tumor predisposition (paragangliomas). |
| Succinyl-CoA Synthetase Deficiency | Mutations in SUCLG1 or SUCLA2. Impairs nucleoside diphosphate kinase interaction. | Mild methylmalonic aciduria. | Severe encephalomyopathy, mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like features, associated with mtDNA depletion. |
| Fumarase Deficiency | Defect in Fumarate Hydratase. | Massive excretion of fumaric acid and elevated succinate. | Severe infantile encephalopathy, brain malformations (polymicrogyria), and facial dysmorphism. |
| Pyruvate Carboxylase (PC) Deficiency | Anaplerotic defect preventing conversion of pyruvate to oxaloacetate. | Elevated lactate, pyruvate, alanine, and ketones. Type B shows severe lactic acidosis, hyperammonemia, and hypercitrullinemia. | Type A: lactic acidosis and developmental delay. Type B: neonatal coma, urea cycle failure, and early death. Type C: benign. |
Clinical Features
| System | Manifestations |
|---|---|
| Neurologic | Leigh syndrome, global developmental delay, regression of milestones, intractable epilepsy, and severe central hypotonia. Movement disorders include dystonia, ataxia, and choreoathetosis. |
| Cardiac | Hypertrophic or dilated cardiomyopathy, particularly in SDH and Fumarase defects. |
| Hepatic And Metabolic | Liver failure or dysfunction in PC deficiency. Recurrent severe high anion gap metabolic acidosis (lactic acidosis) triggered by catabolic stress. |
Investigations
Screening And Metabolites
| Test | Diagnostic Findings |
|---|---|
| Initial Screen | High anion gap metabolic acidosis, elevated lactate with increased Lactate:Pyruvate ratio (>20). Hypoglycemia is present in PC deficiency due to gluconeogenesis impairment. |
| Ammonia | Elevated in PC deficiency Type B due to oxaloacetate depletion disrupting the urea cycle. |
| Urine Organic Acids | Massive fumaric acid excretion (Fumarase deficiency). Elevated alpha-ketoglutarate and branched-chain hydroxyacids (Alpha-KGDH deficiency). |
Neuroimaging And Confirmation
- MRI Brain: Bilateral symmetric T2 hyperintensities in the basal ganglia, thalamus, and brainstem indicating Leigh syndrome. Corpus callosum agenesis or cysts specifically suggest Pyruvate Carboxylase defects.
- Confirmation: Whole Exome Sequencing (WES) or targeted gene panels (DLD, SDHA, FH, PC) are the standard of care, largely replacing invasive enzymatic assays.
Management
Acute Management
- Correct acidosis utilizing bicarbonate or citrate administration.
- Administer intravenous 10% Dextrose to reverse catabolism and promote anabolism.
- Manage hyperammonemia in PC Type B with nitrogen scavengers or dialysis.
Chronic Maintenance And Cofactors
| Modality | Rationale And Options |
|---|---|
| Dietary Modification | High carbohydrate and protein diet is recommended for PC deficiency to prevent gluconeogenic stress. |
| Anaplerotic Therapy | Triheptanoin (C7 oil) provides propionyl-CoA/succinyl-CoA to bypass early blocks. Aspartate and citrate supplementation replenishes the oxaloacetate pool in PC deficiency. |
| Cofactor Supplementation | Thiamine (B1) targets Alpha-KGDH. Lipoic acid supplements E3 subunit defects. Biotin is essential for Pyruvate Carboxylase. |